BROADLY NEUTRALIZING ANTIBODIES OFFER NEW PROSPECTS FOR AN HIV VACCINE

Orateur : Pascal POIGNARD (Professor of Virology / Institut de Biologie et Pathologie / Département des Agents Infectieux / CHU Grenoble Alpes & Group leader / Institut de Biologie Structurale / CEA-CNRS-Université Grenoble Alpes & Adjunct Professor / Department of Immunology and Microbial Science / The Scripps Research Institute / La Jolla, Californie)

The immune response induced by HIV infection comprises in a subset of individuals broad and potent neutralizing antibodies (bNAbs) capable of blocking the replication of a large fraction of global HIV-1 isolates. The elicitation of such Abs prior to infection would presumably protect against infection by most circulating HIV strains and is thus considered one of the highest priorities of HIV vaccine research. However, no vaccine candidate has been successful at eliciting bnAbs thus far. We will review the latest findings and research that may lead to the development of a preventive Ab-based HIV vaccine.

Télécharger dans mon agenda